{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:50:11Z","timestamp":1790992211189,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001734","name":"University of Copenhagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation Centre of Research Excellence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Clinical guidelines often recommend treating individuals based on their cardiovascular risk. We revisit this paradigm and quantify the efficacy of three treatment strategies: (i) overall prescription, i.e. treatment to all individuals sharing the eligibility criteria of a trial; (ii) risk-stratified prescription, i.e. treatment only to those at an elevated outcome risk; and (iii) prescription based on predicted treatment responsiveness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We reanalysed the PROSPER randomized controlled trial, which included individuals aged 70\u201382 years with a history of, or risk factors for, vascular diseases. We conducted the derivation and internal\u2013external validation of a model predicting treatment responsiveness. We compared with placebo (n = 2913): (i) pravastatin (n = 2891); (ii) pravastatin in the presence of previous vascular diseases and placebo in the absence thereof (n = 2925); and (iii) pravastatin in the presence of a favourable prediction of treatment response and placebo in the absence thereof (n = 2890). We found an absolute difference in primary outcome events composed of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke, per 10 000 person-years equal to: \u221278 events (95% CI, \u2212144 to \u221212) when prescribing pravastatin to all participants; \u221266 events (95% CI, \u2212114 to \u221218) when treating only individuals with an elevated vascular risk; and \u2212103 events (95% CI, \u2212162 to \u221244) when restricting pravastatin to individuals with a favourable prediction of treatment response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pravastatin prescription based on predicted responsiveness may have an encouraging potential for cardiovascular prevention. Further external validation of our results and clinical experiments are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ISRCTN40976937.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwad383","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T18:17:57Z","timestamp":1702405077000},"page":"945-953","source":"Crossref","is-referenced-by-count":5,"title":["The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: an application to the PROSPER randomized controlled trial"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-7212","authenticated-orcid":false,"given":"Tri-Long","family":"Nguyen","sequence":"first","affiliation":[{"name":"Section of Epidemiology, Department of Public Health, University of Copenhagen , \u00d8ster Farimagsgade 5, DK-1356 Copenhagen K , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Trompet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Centre , Leiden , The Netherlands"},{"name":"Departments of Gerontology and Geriatrics, Leiden University Medical Centre , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-3376","authenticated-orcid":false,"given":"John B","family":"Brodersen","sequence":"additional","affiliation":[{"name":"Centre of General Practice, Department of Public Health, University of Copenhagen , Copenhagen , Denmark"},{"name":"Primary Health Care Research Unit , Region Zealand , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2397-6052","authenticated-orcid":false,"given":"Jeroen","family":"Hoogland","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University , Utrecht , The Netherlands"},{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Centers , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1790-2719","authenticated-orcid":false,"given":"Thomas P A","family":"Debray","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University , Utrecht , The Netherlands"},{"name":"Smart Data Analysis and Statistics B.V. , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Centre of Research Excellence for Heart Failure Prevention and Treatment, University of Glasgow , Glasgow , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3246-8359","authenticated-orcid":false,"given":"J Wouter","family":"Jukema","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Centre , Leiden , The Netherlands"},{"name":"Durrer Center for Cardiovascular Research, Netherlands Heart Institute , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi G J","family":"Westendorp","sequence":"additional","affiliation":[{"name":"Section of Epidemiology, Department of Public Health, University of Copenhagen , \u00d8ster Farimagsgade 5, DK-1356 Copenhagen K , Denmark"},{"name":"Center for Healthy Ageing, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"2024060223510279800_zwad383-B1","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1001\/jama.1992.03490170092032","article-title":"Evidence-Based medicine","volume":"268","author":"Guyatt","year":"1992","journal-title":"JAMA"},{"key":"2024060223510279800_zwad383-B2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1745-6215-11-85","article-title":"Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal","volume":"11","author":"Kent","year":"2010","journal-title":"Trials"},{"key":"2024060223510279800_zwad383-B3","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0140-6736(95)90120-5","article-title":"Can overall results of clinical trials be applied to all patients?","volume":"345","author":"Rothwell","year":"1995","journal-title":"Lancet"},{"key":"2024060223510279800_zwad383-B4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"2024060223510279800_zwad383-B5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.298.10.1209","article-title":"Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification","volume":"298","author":"Kent","year":"2007","journal-title":"JAMA"},{"key":"2024060223510279800_zwad383-B6","first-page":"2075","article-title":"Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials","volume":"45","author":"Kent","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2024060223510279800_zwad383-B7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The predictive approaches to treatment effect heterogeneity (PATH) statement","volume":"172","author":"Kent","year":"2019","journal-title":"Ann Intern Med"},{"key":"2024060223510279800_zwad383-B8","doi-asserted-by":"crossref","first-page":"k4245","DOI":"10.1136\/bmj.k4245","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"key":"2024060223510279800_zwad383-B9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The predictive approaches to treatment effect heterogeneity (PATH) statement: explanation and elaboration","volume":"172","author":"Kent","year":"2019","journal-title":"Ann Intern Med"},{"key":"2024060223510279800_zwad383-B10","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bmj.311.7016.1356","article-title":"An evidence based approach to individualising treatment","volume":"311","author":"Glasziou","year":"1995","journal-title":"BMJ"},{"key":"2024060223510279800_zwad383-B11","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"2024060223510279800_zwad383-B12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2024060223510279800_zwad383-B13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024060223510279800_zwad383-B14","doi-asserted-by":"crossref","first-page":"e1002410","DOI":"10.1371\/journal.pmed.1002410","article-title":"Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials","volume":"14","author":"Basu","year":"2017","journal-title":"PLoS Med"},{"key":"2024060223510279800_zwad383-B15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"2024060223510279800_zwad383-B16","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(20)32114-0","article-title":"Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation","volume":"396","author":"Takahashi","year":"2020","journal-title":"Lancet"},{"key":"2024060223510279800_zwad383-B17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2024060223510279800_zwad383-B18","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","article-title":"The design of a prospective study of pravastatin in the elderly at risk (PROSPER)","volume":"84","author":"Shepherd","year":"1999","journal-title":"Am J Cardiol"},{"key":"2024060223510279800_zwad383-B19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jclinepi.2020.05.022","article-title":"Counterfactual clinical prediction models could help to infer individualized treatment effects in randomized controlled trials\u2014an illustration with the international stroke trial","volume":"125","author":"Nguyen","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2024060223510279800_zwad383-B20","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1002\/sim.9154","article-title":"A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint","volume":"40","author":"Hoogland","year":"2021","journal-title":"Stat Med"},{"key":"2024060223510279800_zwad383-B21","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1002\/sim.8981","article-title":"Developing more generalizable prediction models from pooled studies and large clustered data sets","volume":"40","author":"de Jong","year":"2021","journal-title":"Stat Med"},{"key":"2024060223510279800_zwad383-B22","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1002\/sim.5732","article-title":"A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis","volume":"32","author":"Debray","year":"2013","journal-title":"Stat Med"},{"key":"2024060223510279800_zwad383-B23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/sim.1691","article-title":"Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"2024060223510279800_zwad383-B24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jclinepi.2015.04.005","article-title":"Prediction models need appropriate internal, internal-external, and external validation","volume":"69","author":"Steyerberg","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2024060223510279800_zwad383-B25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2021.03.025","article-title":"Internal\u2013external cross-validation helped to evaluate the generalizability of prediction models in large clustered datasets","volume":"137","author":"Takada","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2024060223510279800_zwad383-B26","doi-asserted-by":"crossref","first-page":"i2416","DOI":"10.1136\/bmj.i2416","article-title":"Prediction models for cardiovascular disease risk in the general population: systematic review","volume":"353","author":"Damen","year":"2016","journal-title":"BMJ"},{"key":"2024060223510279800_zwad383-B27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jclinepi.2019.05.029","article-title":"Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting","volume":"114","author":"van Klaveren","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2024060223510279800_zwad383-B28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jclinepi.2015.02.012","article-title":"Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions","volume":"68","author":"van Klaveren","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2024060223510279800_zwad383-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for cox's proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"key":"2024060223510279800_zwad383-B30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1467-9868.2011.01004.x","article-title":"Strong rules for discarding predictors in lasso-type problems","volume":"74","author":"Tibshirani","year":"2012","journal-title":"J R Stat Soc Ser B (Stat Methodol)"},{"key":"2024060223510279800_zwad383-B31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/EDE.0000000000000991","article-title":"Selecting optimal subgroups for treatment using many covariates","volume":"30","author":"VanderWeele","year":"2019","journal-title":"Epidemiology"},{"key":"2024060223510279800_zwad383-B32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","article-title":"A solution to the problem of monotone likelihood in cox regression","volume":"57","author":"Heinze","year":"2004","journal-title":"Biometrics"},{"key":"2024060223510279800_zwad383-B33","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"de Vries","year":"2021","journal-title":"Eur Heart J"},{"key":"2024060223510279800_zwad383-B34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00228-015-1994-9","article-title":"Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies","volume":"72","author":"Trompet","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2024060223510279800_zwad383-B35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1532-5415.2005.00635.x","article-title":"Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an aged\u20ac statin interaction","volume":"54","author":"Micale Foody","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"2024060223510279800_zwad383-B36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/07853890.2010.546363","article-title":"Prognostic significance of serum cholesterol, lathosterol, and sitosterol in old age; a 17-year population study","volume":"43","author":"Tilvis","year":"2011","journal-title":"Ann Med"},{"key":"2024060223510279800_zwad383-B37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Armitage","year":"2019","journal-title":"Lancet"},{"key":"2024060223510279800_zwad383-B38","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/archinte.163.13.1549","article-title":"High-Density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age","volume":"163","author":"Weverling-Rijnsburger","year":"2003","journal-title":"Arch Intern Med"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwad383\/55675924\/zwad383.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/8\/945\/58009488\/zwad383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/8\/945\/58009488\/zwad383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T23:51:45Z","timestamp":1717372305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/8\/945\/7470717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12,12]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwad383","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2023,12,12]]}}}